Anthony V D'Amico

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
    Lancet Oncol 13:189-95. 2012
  2. ncbi Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    Cancer 113:3290-7. 2008
  3. ncbi Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancer
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 77:1329-37. 2010
  4. ncbi Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy
    Anthony D'Amico
    Genitourinary Radiation Oncology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    BJU Int 99:13-6; discussion 17-8. 2007
  5. ncbi Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital, Boston, MA 02215, USA
    J Clin Oncol 27:3923-8. 2009
  6. ncbi Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Cancer 110:56-61. 2007
  7. ncbi Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Cancer 110:1723-8. 2007
  8. ncbi Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 71:9-15. 2008
  9. ncbi Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    JAMA 299:289-95. 2008
  10. ncbi Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 75:10-5. 2009

Detail Information

Publications80

  1. ncbi Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
    Lancet Oncol 13:189-95. 2012
    ..Thus, we assessed whether prostate-specific antigen (PSA) values can act as an early surrogate for prostate cancer-specific mortality (PCSM)...
  2. ncbi Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    Cancer 113:3290-7. 2008
    ..The authors estimated and characterized mortality after androgen suppression therapy (AST) use in men with newly diagnosed localized and recurrent prostate cancer...
  3. ncbi Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancer
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 77:1329-37. 2010
    ....
  4. ncbi Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy
    Anthony D'Amico
    Genitourinary Radiation Oncology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    BJU Int 99:13-6; discussion 17-8. 2007
    ....
  5. ncbi Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital, Boston, MA 02215, USA
    J Clin Oncol 27:3923-8. 2009
    ..We estimated the risk of prostate cancer (PC) -specific mortality (PCSM) after brachytherapy alone or in conjunction with androgen suppression therapy (AST), external-beam radiation therapy (EBRT), or both in men with high-risk PC...
  6. ncbi Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Cancer 110:56-61. 2007
    ..Estimates of prostate cancer-specific mortality (PCSM) were determined after radical prostatectomy (RP) or radiation therapy (RT) in men with >or=1 high-risk factors...
  7. ncbi Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Cancer 110:1723-8. 2007
    ..The authors evaluated whether the duration of androgen suppression (AS) after the completion of hormone therapy (HT) was associated with the risk of prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM)...
  8. ncbi Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 71:9-15. 2008
    ..5 Tesla endorectal magnetic resonance imaging (eMRI) was associated with the risk of recurrence after radiation (RT) and 6 months of AST...
  9. ncbi Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    JAMA 299:289-95. 2008
    ..Comorbidities may increase the negative effects of specific anticancer treatments such as androgen suppression therapy (AST)...
  10. ncbi Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 75:10-5. 2009
    ..To assess whether the risk of death is associated with the time to testosterone recovery (TTR) after radiotherapy (RT) and hormonal therapy (HT) for prostate cancer (PCa)...
  11. ncbi p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682)
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital, Boston, Massachusetts 02215, USA
    Urology 71:933-7. 2008
    ..It has been hypothesized that abnormal p53 protein expression is associated with a worse prognosis after radiation (RT) and androgen suppression therapy (AST). This hypothesis was prospectively tested...
  12. ncbi Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy
    Anthony V D'Amico
    Department of Radiation, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 26:2979-83. 2008
    ..We determined the risk of recurrence in men enrolled on a randomized trial for prostate cancer who were treated with radiation therapy (RT) alone or in conjunction with combined or less than combined androgen suppression therapy (AST)...
  13. ncbi Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death
    Anthony V D'Amico
    Brigham and Women s Hospital and Dana Farber Cancer Institute, Department of Radiation Oncology, Boston, MA, USA
    BJU Int 106:1618-22. 2010
    ....
  14. ncbi Luteinizing-hormone releasing hormone therapy and the risk of death from Alzheimer disease
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, MA, USA
    Alzheimer Dis Assoc Disord 24:85-9. 2010
    ..We evaluated the risk of death from Alzheimer disease (AD) in men with prostate cancer undergoing treatment with or without a luteinizing-hormone releasing hormone (LHRH) agonist...
  15. ncbi Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer
    Anthony V D'Amico
    Brigham and Women s Hospital, Boston, MA 02115, USA
    J Clin Oncol 29:4682-7. 2011
    ....
  16. ncbi Coronary artery revascularization and the risk of death in men with prostate cancer
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital, Dana Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Urol 186:898-902. 2011
    ..We investigated whether the decrease in death from cardiovascular disease, a major competing risk, explains the observed increase in prostate cancer specific mortality before 1992...
  17. ncbi Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death
    Toni K Choueiri
    Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Cancer 116:1887-92. 2010
    ..BCR) as a time-dependent covariate (t) after radical prostatectomy (RP) for prostate cancer was associated with the risk of death and whether salvage therapy with radiotherapy (RT) and/or hormonal therapy (HT) can lessen this risk..
  18. ncbi Reduced penile size and treatment regret in men with recurrent prostate cancer after surgery, radiotherapy plus androgen deprivation, or radiotherapy alone
    Arti Parekh
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Urology 81:130-4. 2013
    ..To report the relative incidence of the perceived reduction in penile size across prostate cancer treatment modalities and to describe its effect on quality of life and treatment regret...
  19. ncbi Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality
    Henry K Tsai
    Harvard Radiation Oncology Program, Harvard Medical School, Boston, MA 02215, USA
    J Natl Cancer Inst 99:1516-24. 2007
    ..We investigated whether androgen deprivation therapy (ADT) use is associated with an increased risk of death from cardiovascular causes in patients treated for localized prostate cancer...
  20. ncbi Comorbidity, body mass index, and age and the risk of nonprostate-cancer-specific mortality after a postradiation prostate-specific antigen recurrence
    Paul L Nguyen
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer 116:610-5. 2010
    ..Therefore, our ability to determine who would benefit from salvage hormonotherapy (HT) would be enhanced if an individual's risk of nonprostate-cancer-specific mortality were known...
  21. ncbi Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Natl Cancer Inst 96:509-15. 2004
    ....
  22. ncbi Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence
    Jennifer Y Wo
    Harvard Radiation Oncology Program, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 27:6000-5. 2009
    ....
  23. ncbi Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy
    Akash Nanda
    Harvard Radiation Oncology Program, Brigham and Women s Hospital Dana Farber Cancer Institute, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 76:1439-44. 2010
    ..a luteinizing hormone-releasing hormone (LHRH) agonist alone affects the risk of prostate cancer-specific mortality (PCSM) in men with localized but high-risk disease treated with radiotherapy...
  24. ncbi Population-based determinants of radical prostatectomy surgical margin positivity
    Stephen B Williams
    Division of Urologic Surgery, Center for Surgery and Public Health, Dana Farber Cancer Institute, Department of Radiation Oncology, Brigham and Women s Hospital, Boston, MA 02115, USA
    BJU Int 107:1734-40. 2011
    ..Prognosis (cohort)...
  25. ncbi Race and survival following brachytherapy-based treatment for men with localized or locally advanced adenocarcinoma of the prostate
    Karen M Winkfield
    Harvard Radiation Oncology Program, Harvard Medical School, Boston, Massachusetts, USA
    Int J Radiat Oncol Biol Phys 81:e345-50. 2011
    ....
  26. ncbi Radiation with or without 6 months of androgen suppression therapy in intermediate- and high-risk clinically localized prostate cancer: a postrandomization analysis by risk group
    Paul L Nguyen
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Int J Radiat Oncol Biol Phys 77:1046-52. 2010
    ..RT alone in men with unfavorable risk localized prostate cancer (PCa), but it is unknown if this benefit applies to all risk subgroups and, in particular, the intermediate-risk group...
  27. ncbi Cardiovascular comorbidity and treatment regret in men with recurrent prostate cancer
    Paul L Nguyen
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    BJU Int 110:201-5. 2012
    ....
  28. ncbi Patient-reported quality of life after salvage brachytherapy for radio-recurrent prostate cancer: A prospective Phase II study
    Paul L Nguyen
    Harvard Radiation Oncology Program, Boston, MA 02115, USA
    Brachytherapy 8:345-52. 2009
    ..Patient-reported quality of life (QOL) after salvage brachytherapy for radiorecurrent prostate cancer has not been well-characterized prospectively...
  29. ncbi Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation
    Paul L Nguyen
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer 117:406-13. 2011
    ....
  30. ncbi Biopsy Gleason score and the duration of testosterone suppression among men treated with external beam radiation and 6 months of combined androgen blockade
    Neil E Martin
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA Department of Statistics, University of Connecticut, Storrs, CT Department of Medical Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    BJU Int 110:1252-6. 2012
    ..In this study, we found that among men treated with 6 months of combined androgen blockade and radiation therapy, higher biopsy Gleason grade was associated with a shorter time to testosterone normalization...
  31. ncbi Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer
    Ayal A Aizer
    Harvard Radiation Oncology Program, Massachusetts General Hospital, Department of Radiation Oncology, 100 Blossom St, Cox 3, Boston, MA 02114, USA
    J Clin Oncol 30:3071-6. 2012
    ..The purpose of this study was to determine whether consultation at a multidisciplinary clinic is associated with selection of active surveillance in patients with low-risk prostate cancer...
  32. ncbi The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection
    Daniel A Wattson
    Harvard Radiation Oncology Program, Department of Radiation Oncology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 82:e773-9. 2012
    ....
  33. ncbi Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction
    Paul L Nguyen
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    Int J Radiat Oncol Biol Phys 82:1411-6. 2012
    ....
  34. ncbi Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy
    Akash Nanda
    Harvard Radiation Oncology Program, Brigham and Women s Hospital Dana Farber Cancer Institute, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 77:147-52. 2010
    ....
  35. ncbi 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Mass 02215, USA
    JAMA 292:821-7. 2004
    ....
  36. ncbi Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure
    Alexandra J Stewart
    Brigham and Women s Hospital, Dana Faber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 23:6556-60. 2005
    ..2 ng/mL was significantly associated with prostate cancer-specific mortality (PCSM)...
  37. ncbi Survival following radiation and androgen suppression therapy for prostate cancer in healthy older men: implications for screening recommendations
    Paul L Nguyen
    Harvard Radiation Oncology Program, Department of Radiation Oncology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 76:337-41. 2010
    ..The U.S. Preventive Services Task Force has recommended against screening men over 75 for prostate cancer. We examined whether older healthy men could benefit from aggressive prostate cancer treatment...
  38. ncbi Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer
    Karen E Hoffman
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 116:2590-5. 2010
    ..The authors of this report compared the use of brachytherapy alone with combined brachytherapy, external-beam radiation to the prostate and seminal vesicles, and androgen-suppression therapy (CMT) in this population...
  39. ncbi Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Natl Cancer Inst 95:1376-83. 2003
    ..Therefore, we evaluated the hypothesis that a short post-treatment PSA doubling time (PSA-DT) after radiation therapy is a surrogate end point for prostate cancer-specific mortality by analyzing two multi-institutional databases...
  40. ncbi Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size
    Paul L Nguyen
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 79:1318-22. 2011
    ..Brachytherapy for prostate cancer can be technically challenging in men with small prostates (≤20 cc), but it is unknown whether their outcomes are different than those of men with larger prostates...
  41. ncbi Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 24:4190-5. 2006
    ....
  42. ncbi Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy
    Ping Zhou
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA, USA
    J Clin Oncol 23:6992-8. 2005
    ..We evaluated predictors of prostate cancer-specific mortality (PCSM) after prostate-specific antigen (PSA) failure after radical prostatectomy (RP) or radiation therapy (RT)...
  43. ncbi The use of supplemental external beam radiotherapy in men with low-risk prostate cancer undergoing brachytherapy before and after the 1999 American Brachytherapy Society Guideline statement
    Arthur K Cheung
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
    Brachytherapy 9:145-50. 2010
    ..We investigated the patterns of care in the community in this patient population before and after the reporting of the ABS guideline...
  44. ncbi Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer
    Henry K Tsai
    Harvard Radiation Oncology Program, Harvard Medical School, Boston, Massachusetts, USA
    Cancer 107:2597-603. 2006
    ..The authors estimated PCSM after radiation therapy with short-course androgen suppression therapy (RT+AST) or radical prostatectomy (RP) in men with clinically localized, intermediate-risk to high-risk prostate cancer...
  45. ncbi Acute gastrointestinal, genitourinary, and dermatological toxicity during dose-escalated 3D-conformal radiation therapy (3DCRT) using an intrarectal balloon for prostate gland localization and immobilization
    Rosemonde Woel
    Joint Center for Radiation Therapy, Brigham and Women s Hospital and Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 62:392-6. 2005
    ..A modified intrarectal balloon (Medrad) was used for prostate gland localization and immobilization...
  46. ncbi Salvage radiation in men after prostate-specific antigen failure and the risk of death
    Shane E Cotter
    Harvard Radiation Oncology Program, Brigham and Women s Hospital Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 117:3925-32. 2011
    ..Whether such a benefit exits in men with a protracted PSA rise in DT (≥ 6 months) is unclear and was examined in the current study...
  47. ncbi Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 22:3726-32. 2004
    ..We investigated whether pretreatment factors predicted time to prostate cancer-specific mortality (PCSM) after conventional-dose and conformal radiation therapy (CRT)...
  48. ncbi Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer 95:275-80. 2002
    ....
  49. ncbi Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    J Urol 172:S42-6; discussion S46-7. 2004
    ..A short posttreatment prostate specific antigen (PSA)-doubling time (DT) following radical prostatectomy or radiation therapy was evaluated as a surrogate end point for prostate cancer specific mortality (PCSM)...
  50. ncbi Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy
    Anthony V D'Amico
    Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, USA
    N Engl J Med 351:125-35. 2004
    ..We evaluated whether men at risk for death from prostate cancer after radical prostatectomy can be identified using information available at diagnosis...
  51. ncbi Maximum vs. mono androgen blockade and the risk of recurrence in men with localized prostate cancer undergoing brachytherapy
    Ronald C Chen
    Harvard Radiation Oncology Program, Harvard Medical School, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 75:36-9. 2009
    ..We examined whether maximum androgen blockade (MAB) is associated with a decreased recurrence risk vs. single-agent androgen suppression (monotherapy) for men undergoing brachytherapy (BT) for localized prostate cancer...
  52. ncbi Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 95:281-6. 2002
    ....
  53. ncbi Type of diabetes mellitus and the odds of Gleason score 8 to 10 prostate cancer
    Josephine Kang
    Harvard Radiation Oncology Program, Brigham and Women s Hospital, Department of Radiation Oncology, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 82:e463-7. 2012
    ..In this study we evaluated whether DM Type 1, 2, or both are associated with high-grade PCa after adjusting for known predictors of high-grade disease...
  54. ncbi Advanced age at diagnosis is an independent predictor of time to death from prostate carcinoma for patients undergoing external beam radiation therapy for clinically localized prostate carcinoma
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, 75 Francis Street, L 2 Level, Boston, MA 02115, USA
    Cancer 97:56-62. 2003
    ....
  55. ncbi Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction
    Akash Nanda
    Harvard Radiation Oncology Program, Brigham and Women s Hospital Dana Farber Cancer Institute, 75 Francis St, ASB1 L2, Boston, MA 02115, USA
    JAMA 302:866-73. 2009
    ..However, it is unknown which comorbid conditions eliminate this survival benefit...
  56. ncbi Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era
    Paul L Nguyen
    Harvard Radiation Oncology Program, Boston, MA, USA
    Int J Radiat Oncol Biol Phys 74:104-9. 2009
    ..We examined the accuracy of this formula in contemporary patients...
  57. ncbi Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors
    Paul L Nguyen
    Harvard Radiation Oncology Program, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 73:659-64. 2009
    ..To determine whether the number of unfavorable risk factors could be used to predict the risk of prostate cancer-specific mortality (PCSM) among men with intermediate- to high-risk prostate cancer...
  58. ncbi Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke
    Julia H Hayes
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    BJU Int 106:979-85. 2010
    ....
  59. ncbi Cardiovascular comorbidity and mortality in men with prostate cancer treated with brachytherapy-based radiation with or without hormonal therapy
    Akash Nanda
    Department of Radiation Oncology, MD Anderson Cancer Center Orlando, Orlando, Florida, USA
    Int J Radiat Oncol Biol Phys 85:e209-15. 2013
    ..To assess the impact of coronary artery disease (CAD) risk factors and sequelae on the risk of all-cause mortality (ACM) in men treated for prostate cancer (PC)...
  60. ncbi Short- vs long-term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node-negative high-risk adenocarcinoma of the prostate
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 109:2004-10. 2007
    ....
  61. ncbi Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortality
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 109:1290-5. 2007
    ....
  62. ncbi Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality
    Christine S Chung
    Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Urology 71:136-40. 2008
    ..2 ng/mL or less) after 8 months of androgen suppression therapy (AST)...
  63. ncbi Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer
    Jason A Efstathiou
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 109:1493-8. 2007
    ..Whether BMI is associated with time to PSA failure was investigated in men treated with androgen suppression therapy (AST) and radiation therapy (RT) for clinically localized prostate cancer...
  64. ncbi Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions
    Anthony V D'Amico
    Departments of Radiation Oncology and Medicine, Cardiovascular Division, Brigham and Women s Hospital and Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 25:2420-5. 2007
    ..We evaluated whether the timing of fatal myocardial infarction (MI) was influenced by the administration of androgen suppression therapy (AST)...
  65. ncbi Predictors of the use of supplemental androgen suppression therapy and external beam radiation in men with high-risk prostate cancer undergoing brachytherapy in community practice
    Jona A Hattangadi
    Harvard Radiation Oncology Program, Boston, MA 02215, USA
    Brachytherapy 10:369-75. 2011
    ....
  66. ncbi Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, 75 Francis Street, Boston, MA 02215, USA
    J Urol 176:S11-5. 2006
    ..We identified factors at diagnosis that are significantly associated with time to prostate cancer specific mortality following radical prostatectomy or external beam radiation therapy...
  67. ncbi Mortality in men with localized prostate cancer treated with brachytherapy with or without neoadjuvant hormone therapy
    Amy M Dosoretz
    Department of Radiation Oncology, Harvard Radiation Oncology Program, Boston, Massachusetts 02115, USA
    Cancer 116:837-42. 2010
    ..Therefore, the objective of the current study was to examine the effect of NHT on the risk of ACM in men with prostate cancer who receive with brachytherapy...
  68. ncbi Defining the rectal dose constraint for permanent radioactive seed implantation of the prostate
    Michele Albert
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
    Urol Oncol 26:147-52. 2008
    ..This study was performed to define the rectal dose constraint that would predict late rectal bleeding requiring argon plasma coagulation (APC) following prostate brachy mono-therapy...
  69. ncbi Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low- and intermediate-risk prostate cancer
    Clair Beard
    Department of Radiation Oncology, Dana Farber Cancer Institute and Brigham and Women s Hospital, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 66:403-7. 2006
    ..To identify an association between perineural invasion (PNI) and cancer-specific survival in patients with prostate cancer after standard-dose external beam radiation therapy (RT)...
  70. ncbi Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy
    Michele Albert
    Department of Radiation Oncology, Brigham and Women s Hospital, 75 Francis Street, L 2 Level, Boston, MA 02115, USA
    Cancer 98:949-54. 2003
    ..This study was designed to estimate the rates of late genitourinary (GU) and rectal toxicity after magnetic resonance image (MRI)-guided prostate brachytherapy exclusively or in conjunction with external beam radiation therapy (EBRT)...
  71. ncbi Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era
    Anthony V D'Amico
    Department of Radiation Oncology, Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 21:2163-72. 2003
    ..To determine whether pretreatment risk groups shown to predict time to prostate cancer-specific mortality (PCSM) after treatment at a single institution retained that ability in a multi-institutional setting...
  72. ncbi Comorbidity and mortality results from a randomized prostate cancer screening trial
    E David Crawford
    University of Colorado Health Sciences Center, Denver, CO, USA
    J Clin Oncol 29:355-61. 2011
    ..However, results analyzed by comorbidity strata remain unknown...
  73. ncbi Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy
    Toni K Choueiri
    Dana Farber Cancer Institute Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Cancer 115:981-7. 2009
    ....
  74. ncbi Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials
    Akash Nanda
    Harvard Radiation Oncology Program, Brigham and Women s Hospital, Boston, MA 02115, USA
    Int J Radiat Oncol Biol Phys 74:1419-23. 2009
    ..To compare prostate-specific antigen (PSA) outcomes in a cohort of men with high-risk prostate cancer based on the presence or absence of any Gleason Grade 5 component (primary, secondary, or tertiary)...
  75. ncbi Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease
    Nils D Arvold
    Harvard Radiation Oncology Program, Harvard Medical School, Boston, Massachusetts, USA
    J Urol 186:91-6. 2011
    ..We estimated the risk of prostate cancer specific mortality following radical prostatectomy or brachytherapy in men with low or intermediate risk prostate cancer using prospectively collected data...
  76. ncbi Comparative effectiveness of minimally invasive vs open radical prostatectomy
    Jim C Hu
    Division of Urologic Surgery, Brigham and Women s Hospital, 45 Francis St, Boston, MA 02115, USA
    JAMA 302:1557-64. 2009
    ..Minimally invasive radical prostatectomy (MIRP) has diffused rapidly despite limited data on outcomes and greater costs compared with open retropubic radical prostatectomy (RRP)...
  77. ncbi Radical retropubic prostatectomy and robotic-assisted laparoscopic prostatectomy: likelihood of positive surgical margin(s)
    Stephen B Williams
    Division of Urology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Urology 76:1097-101. 2010
    ....
  78. ncbi The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer
    Matthew S Katz
    Radiation Oncology Associates, Saints Medical Center, Lowell, MA, USA
    BJU Int 105:1417-22. 2010
    ....
  79. ncbi Biological in situ dose painting for image-guided radiation therapy using drug-loaded implantable devices
    Robert A Cormack
    Department of Radiation Oncology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Int J Radiat Oncol Biol Phys 76:615-23. 2010
    ..We model this new approach for two types of treatment...
  80. ncbi Prostate cancer screening in men 75 years old or older: an assessment of self-reported health status and life expectancy
    Karen E Hoffman
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 183:1798-802. 2010
    ..In this study we evaluated the influence of health status and life expectancy on prostate specific antigen screening in older men in the United States before the 2008 United States Preventive Services Task Force guidelines...